





**Veterinary medicinal products:
authorisations and drug safety
2022**

Authorised veterinary medicinal products (2020 to 2022)¹



Distribution by target animal species 2022

On average, one veterinary medicinal product (VMP) was authorised for just under two target animal species, i.e. in target species terms, there were approximately 1,300 authorisations. Authorisations by the commonest target species (number and percentage) are divided as follows:



¹ Excluding immunological veterinary medicinal products, which have only been Swissmedic's responsibility since they were transferred to the Agency from the Institute of Virology and Immunology (IVI) on 1 January 2023.

In terms of the target species specifically mentioned in the chart, there were 498 authorisations for pets (dogs, cats and «pet» horses) and 638 for livestock (cattle, pigs, «working» horses, sheep and goats) as at the end of 2022. The 139 authorisations for horses break down into 128 for «working» horses and 11 for «pet» horses. The «Other» category includes the following species


in descending order: «Pets excluding ornamental fish» (23 authorisations), ornamental fish (21), ruminants (19) «livestock» (16) «animals» (13), rabbits (12), poultry (11), bees (9), exotics (9), ferrets (6), guinea pigs (6), small rodents (5), exotic birds (5), donkeys (4), zoo and wild animals (2), fish (1), hedgehogs (1), broiler chickens (1) and broiler turkeys (1).

Distribution by ATCvet 2022

The vast majority of authorised veterinary medicinal products were in groups QP: antiparasitic products (24%) and QJ: antiinfectives (22%). The other major groups are QM: musculoskeletal system (10%), QN: nervous system (8%), QA: alimentary tract and metabolism (7%), QG: genito-urinary system and sex hormones (7%) and QD:

dermatologicals (5%). The remaining seven ATC groups account for less than 5% each and together represent less than 20% of all authorised VMPs. The smallest group – QL: antineoplastic and immunomodulating veterinary medicinal products – accounts for just 1.5% of all authorised veterinary medicinal products.

Completed authorisation procedures (2020 to 2022)



Between 2020 and 2022, around half of veterinary medicinal products with known active substances with and without innovation were authorised under Art. 13 TPA², while one veterinary medicinal product with a new active substance and seven veterinary medicinal products with known active

substances with or without innovation were authorised under Art. 14 para. 1 let. a^{bis}. During the same period, one temporary authorisation was granted to urgently plug a supply gap and one notification procedure according to Art. 39 TPLO³ was completed.

² Therapeutic Products Act (SR 812.21)

³ Ordinance of the Swiss Agency for Therapeutic Products on the Simplified Licensing of Therapeutic Products and the Licensing of Therapeutic Products by the Notification Procedure (SR 812.212.23)

Newly authorised veterinary medicinal products 2022

14 new veterinary medicinal products were authorised during 2022: 11 for pets (six for dogs, three for dogs and cats, and one each for cats and «pet» horses) and three for livestock (one for cows, one for bulls and one for bees). The individual authorised veterinary medicinal products were:

Authorisation number	Name	Indication
68100	Cardisure ad us. vet., divisible tablets for dogs	Cardiovascular therapeutic for dogs
68339	Galliprant ad us. vet., tablets for dogs	Relief of pain and inflammation associated with osteoarthritis in dogs
68341	Neptra ad us. vet., ear drops for dogs	Treatment of acute or recurrent canine otitis externa caused by mixed infections of strains of bacteria sensitive to florfenicol and fungi sensitive to terbinafine
68379	Chanhold ad us. vet., spot-on solution for cats and dogs	Antiparasitic for dogs and cats
68387	Epityl flavour 60 mg ad us. vet., divisible tablets for dogs	Antiepileptic for dogs
68392	Rilexine DC 375 mg ad us. vet., intramammary suspension for dry cows	Intramammary suspension for dry cows
68485	Pergoquin 1 mg ad us. vet., tablets for horses	Dopamine agonist for horses
68528	Cylanic ad us. vet., divisible tablets for dogs and cats	Antibiotic for dogs and cats
68630	Metacox 0.5 mg/ml ad us. vet., oral suspension for cats	Non-steroidal anti-inflammatory for cats
68634	Formicpro ad us. vet., impregnated beehive strips for honey bees	Treatment of varroosis caused by <i>Varroa destructor</i> in honey bees (<i>Apis mellifera</i>).
68713	Metrotab ad us. vet., flavoured tablets for dogs and cats	Anti-infective, antiprotozoal agent for dogs and cats
68731	Firodyl ad us. vet., divisible chewable tablets for dogs	For the relief of pain and inflammation associated with osteoarthritis in dogs. For the relief of post-operative pain and inflammation associated with soft-tissue, orthopaedic and dental surgery in dogs.
68940	Apoquel ad us. vet., chewable tablets for dogs	Canine allergic dermatitis
68972	Tribex 10% ad us. vet., oral suspension for cattle	Anthelmintic for the treatment of liverfluke in cattle

Additional indications and target animal species 2022

Authorisation number	Name	Indication
59061	Suprelorin 4.7 mg ad us. vet., implant for dogs (males and females) and cats (males)	Induction of temporary infertility in dogs (males and females) and cats (males)
68382	NexGard Combo Spot-on for cats < 2.5 kg ad us. vet., spot-on solution	For cats with, or at risk of, mixed parasitic infection with cestodes (tapeworms), nematodes (roundworms) and ectoparasites.

Drug safety for veterinary medicinal products 2022

A summary of the main points

- 422 reports: 358 involving small animals (including 254 dogs and 104 cats), 48 involving large animals (including 31 cows/cattle/calves and 11 horses), six reactions in humans
- Most frequent medicinal product types: antiparasitics (141), hormone products (103) products to modulate the nervous system (76), anti-infectives (21)
- 139 cases of suspected lack of efficacy, largely for antiparasitics and hormone products
- 47 cases forwarded by Tox Info Suisse, including 30 cases of accidental ingestion of flavoured tablets by dogs or cats
- 104 cases of human exposure to veterinary medicinal products, most frequently antiparasitic products. 37 cases of confusion with human medicinal products, 32 cases of exposure in young children and 27 cases of skin contact, primarily with solutions.
- Six signals opened, four closed. Examples: Notes on the correct removal of bismuth subnitrate-based teat sealants before milking, warnings on the risks of flunixin-containing veterinary medicinal products for birds that eat carrion and safety precautions for the use of isoflurane-based inhalation anaesthetics.

Credits

Publisher

Swissmedic, Swiss Agency for Therapeutic Products
Authorisation Sector
Veterinary Medicines Division
Hallerstrasse 7
3012 Bern
Switzerland
www.swissmedic.ch

Editors/contacts

Cedric Müntener, Veterinary Assessor
Peter Schmid, Regulatory Manager

Layout and typesetting

Swissmedic, Communication Division